Promising Potential of Merus’s Petosemtamab in HNSCC: A Buy Recommendation
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...
Merus’s Promising Prospects: Buy Rating Highlighted by Positive Data on Peto’s Efficacy in HNSCC
Analyst Ami Fadia of Needham maintained a Buy rating on Merus (MRUS – Research Report), retaining the price target of $85.00.Pick the best ...
Citigroup Issues Positive Forecast for Merus (NASDAQ:MRUS) Stock Price
Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...
Merus Scores Its First FDA Approval For Lung Cancer Drug
Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...
The Pharma Letter2d
Positive early data on Merus’ petosemtamab
Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...
Merus (NASDAQ:MRUS) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...
pharmaphorum6d
Merus grabs first-in-class US approval for NRG1 cancer drug
Bizengri (zenocutuzumab) targets the NRG1 gene and has been cleared by the FDA to treat advanced pancreatic adenocarcinoma ...
NBC Los Angeles8d
Cramer's Lightning Round: Merus is ‘very speculative'
Get top local stories in Southern California delivered to you every morning. Sign up for NBC LA's News Headlines newsletter.
Yahoo Finance5d
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...